Author

L. J. van't Veer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. Goga· 1 shared A. Prahallad· 1 shared A. Ruiz-Saenz· 1 shared B. Hann· 1 shared B. Pan· 1 shared C. A. Dreyer· 1 shared C. Baas· 1 shared C. Cowdrey· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Goga

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors

A. Ruiz-Saenz, C. E. Atreya, C. Wang, B. Pan, C. A. Dreyer, D. Brunen, A. Prahallad, D. P. Munoz, D. J. Ramms, V. Burghi, D. S. Spassov, E. Fewings, Y. C. Hwang, C. Cowdrey, C. Moelders, , J.-P. Coppe

This study identifies a SRC-relayed COX2-inflammatory program that drives resistance to BRAF/MEK/EGFR therapies in BRAFV600E colorectal tumors and shows that co-targeting COX2 improves therapeutic outcomes.

bioRxiv · Oct 20, 2022 · PreprintCancer Biology

Combinatorial immunotherapies overcome MYC-driven immune evasion

J. V. Lee, F. Houseley, C. Yau, D. Van de Mark, R. Nakagawa, G. Hemmati, G. A. Hernandez, J. Winkler, Y. Zhang, S. Samson, C. Baas, L. J. Esserman, L. J. Van't Veer, H. S. Rugo, M. Matloubian, A. Goga

This study shows that MYC-driven immune evasion in TNBC can be reversed by combining immunotherapies, leading to tumor regression in mice.

bioRxiv · May 7, 2021Cancer Biology